Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XAIR

XAIR - Beyond Air Inc Stock Price, Fair Value and News

$1.27-0.08 (-5.93%)
Market Closed

69/100

XAIR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

69/100

XAIR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.26

Target 3M

$1.76

Target 6M

$1.91

XAIR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XAIR Price Action

Last 7 days

-30.2%

Last 30 days

81.4%

Last 90 days

-36.5%

Trailing 12 Months

-83.8%

XAIR RSI Chart

XAIR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XAIR Valuation

Market Cap

10.2M

Price/Earnings (Trailing)

-0.28

Price/Sales (Trailing)

1.75

EV/EBITDA

-0.01

Price/Free Cashflow

-0.39

XAIR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.26

Target 3M

$1.76

Target 6M

$1.91

XAIR Fundamentals

XAIR Revenue

Revenue (TTM)

5.8M

XAIR Earnings

Earnings (TTM)

-36.7M

Earnings Growth (Yr)

40.56%

Earnings Growth (Qtr)

1.71%

XAIR Profitability

Operating Margin

-6.70%

EBT Margin

-650.32%

Return on Equity

-287.89%

Return on Assets

-118.38%

Free Cashflow Yield

-257.06%

XAIR Investor Care

Shares Dilution (1Y)

121.91%

Diluted EPS (TTM)

-6.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.7M4.8M5.8M0
20241.2M1.8M2.3M3.0M
20230702.9K591.9K833.9K
2021873.1K000
20201.4M1.3M1.1M1.0M
20197.7M6.1M4.6M3.0M
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About Beyond Air Inc

XAIR
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
 CEO
 WEBSITEbeyondair.net
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES98

Beyond Air Inc Frequently Asked Questions

XAIR is the stock ticker symbol of Beyond Air Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Beyond Air Inc is 10.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XAIR's fair value in chart for subscribers.

The fair value guage provides a quick view whether XAIR is over valued or under valued. Whether Beyond Air Inc is cheap or expensive depends on the assumptions which impact Beyond Air Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XAIR.

As of Wed Jan 28 2026, XAIR's PE ratio (Price to Earnings) is -0.28 and Price to Sales (PS) ratio is 1.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XAIR PE ratio will change depending on the future growth rate expectations of investors.